KORU Medical Systems, Inc. (then Repro Med Systems, Inc.) — Form 10-K
Reporting period: Fiscal year ended February 28, 2017, compared with the year ended February 29, 2016. The filing identifies the registrant as Repro Med Systems, Inc., doing business as RMS Medical Products; it is an annual report, not a standalone 2016 fourth-quarter filing.
Business context
The company designs, manufactures and markets portable medical devices, principally the FREEDOM mechanical infusion system and related supplies, and the RES-Q-VAC portable suction system. It operates as one segment. The FREEDOM System is focused on ambulatory and home infusion, including subcutaneous immune globulin (SCIg) therapy.
Financial performance and liquidity
| Metric | FY 2017 | FY 2016 |
|---|---|---|
| Net sales | $12.294 million | $12.247 million |
| Gross profit / gross margin | $7.570 million / 61.6% | $7.603 million / 62.1% |
| Operating income (loss) | ($736,251) | $1.181 million |
| Net income (loss) | ($534,999) | $782,864 |
| Net margin | (4.4%) | 6.4% |
| Cash from (used in) operations | ($331,616) | $1.915 million |
- Revenue was nearly flat, up 0.4%. Domestic sales were $10.223 million and international sales were $2.071 million. Management said approximately $0.4 million of orders shipped after year-end because of product availability and timing.
- SG&A rose 30.7% to $7.768 million, primarily reflecting $1.502 million of litigation and regulatory-related professional fees, plus higher operations and compliance costs. R&D increased to $237,486 from $207,282.
- Cash and cash equivalents were $3.313 million at year-end, down from $4.202 million; certificates of deposit were $262,314. Current assets were $6.780 million and current liabilities were $1.389 million, implying working capital of about $5.390 million and a current ratio of about 4.9.
- Total assets were $8.170 million; total liabilities were $1.494 million and stockholders’ equity was $6.676 million. The balance sheet shows no borrowings or debt.
- Investing cash outflow was $416,329, including $203,125 for property and equipment and $212,008 for patents. Financing cash outflow was $140,739, mainly stock repurchases and payment for cancelled shares.
- Management’s non-GAAP normalized EBITDA was $1.026 million versus $1.928 million in FY 2016; normalized net income was $500,276 versus $1.143 million. These measures add back professional fees related to litigation and regulatory matters and are not GAAP results.
Material changes and developments
- The company moved from prior-year GAAP net income to a net loss, as substantially higher SG&A outweighed stable revenue and gross profit.
- In October 2016, RMS began commercializing its adjustable Precision Flow Rate Controller in Europe and Canada after receiving a CE Mark; the company was preparing an FDA clearance application.
- Germany approved reimbursement for the FREEDOM System in January 2017. Management also reported new international customers and expected sales contribution over the following 12–18 months.
- Effective January 1, 2017, the 21st Century Cures Act changed Medicare Part B infusion-drug reimbursement. Management cited a potential four-year gap before a separate home-infusion service payment takes effect in 2021.
- The board approved changing the fiscal year-end from February 28 to December 31. The company expected a transition filing covering ten months ending December 31, 2017.
- A voluntary correction and removal of certain tubing and needle sets due to defective packaging was completed in May 2016; the company reported no field complaints or adverse events.
Outlook, risks and contingencies
- Management expects the SCIg and home-infusion markets to expand and believes lower-cost FREEDOM products may benefit from cost pressure on competing systems. No quantified revenue or earnings guidance was provided.
- The FDA Warning Letter remained unresolved at the report date. Following inspections and additional Form 483 observations, RMS said it was working with the FDA toward closure, but acknowledged that an unsatisfactory resolution could materially harm operations, financial condition and cash flows.
- EMED Technologies patent litigation remained ongoing. The Patent Trial and Appeal Board invalidated claims asserted under one patent in January 2017, but EMED appealed; a separate patent reexamination and California litigation continued, including a pending motion seeking to restrict sales of three products in California. Outcomes and potential financial effects were uncertain.
- One U.S. distributor generated approximately 56.1% of gross product revenue, creating significant customer and channel concentration. Certain components also rely on single suppliers, and the company said input-cost increases may not always be recoverable through pricing.
- The filing identifies reimbursement changes, competition, product acceptance, regulatory approvals, capital availability, supplier continuity, patent enforcement and litigation as material business uncertainties.
- Management believed cash and expected operating cash generation would fund operations for at least 12 months. However, operating cash flow turned negative and cash declined year over year.
- Management disclosed that former litigation counsel waived collection of approximately $0.5 million in unpaid invoices; the company reversed the fees. RMS said it did not believe it owed the amounts.
Most important facts for investors to verify
- Current status and consequences of FDA Warning Letter closure and subsequent compliance observations.
- Developments in the EMED cases, including the appeal of the PTAB invalidation and the pending California injunction motion.
- Whether delayed shipments and new international markets translate into sustained revenue growth, and whether the 56.1% customer concentration changes.
- Effects of Medicare reimbursement changes on home-infusion access, specialty-pharmacy participation and FREEDOM System demand.
- Cash conversion, inventory growth and ongoing litigation, regulatory, facility-expansion and product-development spending.
- Transition-year reporting following the fiscal year-end change; the filing’s audited financial statements received an unqualified opinion, while management—not the auditor—reported effective internal controls.